A Study to Evaluate Droperidol Use in the Emergency Department and the Effect on QTc

Overview

About this study

The purpose of this study is to study the length of the QTc interval in patients receiving the standard of care dose of intravenous droperidol for headache or migraine, nausea, pain, and indications other than agitation over 30 minutes.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults and children 12 years of age or older.
  • Patients receiving droperidol in the ED on the cardiac monitor for indications other than agitation.

Exclusion Criteria:

  • Patient receiving droperidol for agitation.
  • Patients under 12 years of age.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Fernanda Bellolio, M.D., M.S.

Contact us for the latest status

Contact information:

Fernanda Bellolio M.D., M.S.

(507)255-1845

Bellolio.Fernanda@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available